Beacon ADC Cited in mAbs Journal
Beacon ADC, an innovative platform for antibody-drug-conjugate (ADC) drug development data, has been cited in a recent mAbs publication titled “Exploration of the antibody-drug conjugate clinical landscape” by Maecker et al, (DOI: 10.1080/19420862.2023.2229101). The study highlights the role Beacon ADC can play in supporting high-quality, data-driven research in the fast-growing field of ADC therapeutics.
The study aimed to examine the evolution of ADC design and the strategic choices behind payload selection.
Maecker et al used Beacon ADC to access and analyze detailed information on clinical-stage ADCs, including payload types, targeting tumor antigens, and linker technologies. The platform enabled the authors to contextualize their findings within the broader landscape of ADC development and provided valuable insights into emerging trends.
The authors concluded that of the 267 ADCs tested for cancer, only 11 have received FDA approval while 92 have been discontinued. Understanding the reasons for past failures and applying a multifactorial approach—optimizing targets, antibodies, linkers, and payloads—will hopefully lead to more successful ADC development in the future.
What is Beacon ADC?
Beacon ADC is the most comprehensive Antibody-Drug Conjugate (ADC) database available. Providing timely and accurate, market leading, pre-clinical and clinical drug, trial, and commercial intelligence data.
- The Most Comprehensive Way to Search the ADC Drug Development Landscape: Unique search ontologies based on ADC drug and trial characteristics
- Market Leading Approach to ADC Preclinical & Clinical Data Curation: Manual curation of key ADC research and development data points by ADC research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search ADC company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
